High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events

被引:19
作者
Romano, Kara D. [1 ]
Hill, Colin [1 ]
Trifiletti, Daniel M. [1 ]
Peach, M. Sean [1 ]
Horton, Bethany J. [2 ]
Shah, Neil [1 ]
Campbell, Dylan [1 ]
Libby, Bruce [1 ]
Showalter, Timothy N. [1 ]
机构
[1] Univ Virginia, Dept Radiat Oncol, Sch Med, 1240 Lee St,Box 800383, Charlottesville, VA 22908 USA
[2] Univ Virginia, Sch Med, Div Translat Res & Appl Stat, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA
关键词
IMAGE-GUIDED BRACHYTHERAPY; SOCIETY CONSENSUS GUIDELINES; LOCALLY ADVANCED-CARCINOMA; AMERICAN BRACHYTHERAPY; ADAPTIVE BRACHYTHERAPY; WORKING GROUP; VOLUME; DELINEATION; PARAMETERS; SURVIVAL;
D O I
10.1186/s13014-018-1074-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Brachytherapy (BT) is a vital component of the curative treatment of locally advanced cervical cancer. The American Brachytherapy Society has published guidelines for high dose rate (HDR) BT with recommended dose limits. However, recent reports suggest lower doses may be needed to avoid toxicity. The purpose of this study is to investigate incidence and predictive factors influencing gastrointestinal (GI) and genitourinary (GU) toxicity following HDR intracavitary brachytherapy for locally advanced cervical cancer. Methods: We retrospectively evaluated a cohort of patients with locally advanced cervical cancer who received CT-based HDR BT. Cumulative doses were calculated using the linear-quadratic model. Statistical analyses were used to investigate clinical and dosimetric predictors of GI and GU toxicity following HDR brachytherapy according to CTCAE v4.0 grading criteria. Results: Fifty-six women with FIGO IB1 - IVA cervical cancer were included. The overall rate of any GU adverse event (Grade 1+) was 23.3% (n = 13) and severe adverse events (Grade 3+) was 7.1% (n = 4). Of those, the bladder equivalent dose in 2- Gray (Gy) fractions (EQD(2)) D-2cc was >= 80 for three of the four patients. The overall rate of any GI adverse event was 26.8% (n = 15) and the rate of severe adverse events was 14.3% (n = 8). Of those, six of the eight patients had a rectal EQD(2) D-2cc >= 65 Gy and seven patients had a sigmoid D-2cc >= 65 Gy. Amongst clinically meaningful factors for development of adverse events (i.e. diabetes, smoking status, ovoid size, and treatment duration), there were no statistically significant prognostic factors identified. Conclusions: Severe adverse events are observed even with adherence to current ABS guidelines. In the era of recent multi-institutional study results, our data also supports more stringent dosimetric goals. We suggest cumulative D2cc dose limits of less than 80 Gy for the bladder and less than 65 Gy for the rectum and sigmoid.
引用
收藏
页数:10
相关论文
共 26 条
[1]  
[Anonymous], 2016, NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer
[2]   DOSIMETRIC AND CLINICAL RESULTS OF A FRENCH PROSPECTIVE STUDY OF 3D BRACHYTHERAPY FOR CERVIX CARCINOMA [J].
Charra-Brunaud, C. ;
Levitchi, M. ;
Delannes, M. ;
Haie-Meder, C. ;
Quetin, P. ;
Kerr, C. ;
Thomas, L. ;
Barillot, I. ;
Peiffert, D. .
RADIOTHERAPY AND ONCOLOGY, 2011, 99 :S57-S57
[3]   Comparative analysis of rectal dose parameters in image-guided high-dose-rate brachytherapy for cervical cancer with and without a rectal retractor [J].
Gaudet, Marc ;
Lim, Peter ;
Yuen, Conrad ;
Zhang, Susan ;
Spadinger, Ingrid ;
Dubash, Rustom ;
Aquino-Parsons, Christina .
BRACHYTHERAPY, 2014, 13 (03) :257-262
[4]   DOSE EFFECT RELATIONSHIP FOR LATE SIDE EFFECTS OF THE RECTUM AND URINARY BLADDER IN MAGNETIC RESONANCE IMAGE-GUIDED ADAPTIVE CERVIX CANCER BRACHYTHERAPY [J].
Georg, Petra ;
Poetter, Richard ;
Georg, Dietmar ;
Lang, Stefan ;
Dimopoulos, Johannes C. A. ;
Sturdza, Alina E. ;
Berger, Daniel ;
Kirisits, Christian ;
Doerr, Wolfgang .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (02) :653-657
[5]   Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group* (I):: concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV [J].
Haie-Meder, C ;
Pötter, R ;
Van Limbergen, E ;
Briot, E ;
De Brabandere, M ;
Dimopoulos, J ;
Dumas, I ;
Hellebust, TP ;
Kirisits, C ;
Lang, SF ;
Muschitz, S ;
Nevinson, J ;
Nulens, A ;
Petrow, P ;
Wachter-Gerstner, N .
RADIOTHERAPY AND ONCOLOGY, 2005, 74 (03) :235-245
[6]   Trends in the Utilization of Brachytherapy in Cervical Cancer in the United States [J].
Han, Kathy ;
Milosevic, Michael ;
Fyles, Anthony ;
Pintilie, Melania ;
Viswanathan, Akila N. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (01) :111-119
[7]   Bladder distension improves the dosimetry of organs at risk during intracavitary cervical high-dose-rate brachytherapy [J].
Harmon, Grant ;
Chinsky, Bonnie ;
Surucu, Murat ;
Harkenrider, Matthew ;
Small, William, Jr. .
BRACHYTHERAPY, 2016, 15 (01) :30-34
[8]   Toxicities and dose-volume histogram parameters of MRI-based brachytherapy for cervical cancer [J].
Kim, Youngkyong ;
Kim, Yeon-Joo ;
Kim, Joo-Young ;
Lim, Young Kyung ;
Jeong, Chiyoung ;
Jeong, Jonghwi ;
Kim, Meyoung ;
Lim, Myong Cheol ;
Seo, Sang-Soo ;
Park, Sang-Yoon .
BRACHYTHERAPY, 2017, 16 (01) :116-125
[9]   Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study [J].
Kirchheiner, Kathrin ;
Nout, Remi A. ;
Lindegaard, Jacob C. ;
Haie-Meder, Christine ;
Mahantshetty, Umesh ;
Segedin, Barbara ;
Jurgenliemk-Schulz, Ina M. ;
Hoskin, Peter J. ;
Rai, Bhavana ;
Dorr, Wolfgang ;
Kirisits, Christian ;
Bentzen, Soren M. ;
Potter, Richard ;
Tanderup, Kari .
RADIOTHERAPY AND ONCOLOGY, 2016, 118 (01) :160-166
[10]   American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer [J].
Mayadev, Jyoti ;
Viswanathan, Akila ;
Liu, Yu ;
Li, Chin-Shang ;
Albuquerque, Kevin ;
Damato, Antonio L. ;
Beriwal, Sushil ;
Erickson, Beth .
BRACHYTHERAPY, 2017, 16 (01) :22-43